Brought to you by 
Ipsen pays $23mm up front for exclusive rights to Lexicon's Phase III carcinoid syndrome candidate
02 Feb 2023
Executive Summary
Ipsen licensed exclusive global marketing rights (outside of the US, Canada, and Japan) to Lexicon Pharmaceuticals Inc.’s telotristat, which is in Phase III trials for carcinoid syndrome.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen pays $23mm up front for exclusive rights to Lexicon's Phase III carcinoid syndrome candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice